

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information
Full Analysis Dataset : FRANCE**

Number of prospective patients (C1+C2+C3+C4+C5)	1800
Number of enrolling sites	37
Number of enrolling countries	1
Enrolment period	02AUG2010 - 27JUL2016
Duration of enrolment (months)	71.9

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : FRANCE**

Region	Country	Cohort 1 Retrospective patients (N=261)	Cohort 1 Prospective patients (N=268)	Cohort 2 (N=470)	Cohort 3 (N=330)	Cohort 4 (N=331)	Cohort 5 (N=401)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Europe	France	261	268	470	330	331	401	1800	1399

**Table 03 : Demographic Characteristics
Full Analysis Dataset : FRANCE**

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Sex, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	Male	136 (52.1)	147 (54.9)	248 (52.8)	190 (57.6)	192 (58.0)	214 (53.4)	991 (55.1)	777 (55.5)
	Female	125 (47.9)	121 (45.1)	222 (47.2)	140 (42.4)	139 (42.0)	187 (46.6)	809 (44.9)	622 (44.5)
Age at Diagnosis (Years)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	Mean (SD)	73.5 (10.4)	73.7 (11.4)	73.5 (11.6)	75.2 (11.5)	74.4 (10.7)	75.1 (11.2)	74.4 (11.3)	74.2 (11.4)
	Median (IQR)	76.0 (67.0 to 81.0)	75.0 (67.5 to 82.0)	76.0 (66.0 to 82.0)	77.0 (68.0 to 85.0)	75.0 (67.0 to 83.0)	77.0 (69.0 to 83.0)	76.0 (67.0 to 83.0)	76.0 (67.0 to 83.0)
	Min to Max	42 to 97	34 to 95	34 to 99	38 to 98	38 to 95	26 to 99	26 to 99	34 to 99
Age Group, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	<65	51 (19.5)	50 (18.7)	104 (22.1)	60 (18.2)	58 (17.5)	61 (15.2)	333 (18.5)	272 (19.4)
	65-74	69 (26.4)	71 (26.5)	102 (21.7)	76 (23.0)	102 (30.8)	105 (26.2)	456 (25.3)	351 (25.1)
	>=75	141 (54.0)	147 (54.9)	264 (56.2)	194 (58.8)	171 (51.7)	235 (58.6)	1011 (56.2)	776 (55.5)
Time since AF Diagnosis (Weeks)	n (missing)	261 (0)	202 (66)	326 (144)	236 (94)	217 (114)	212 (189)	1193 (607)	981 (418)
	Mean (SD)	62.18 (24.44)	1.93 (1.87)	1.11 (1.31)	1.46 (1.55)	1.15 (1.27)	1.34 (1.52)	1.37 (1.52)	1.37 (1.52)
	Median (IQR)	58.70 (40.70 to 83.10)	1.05 (0.40 to 3.40)	0.60 (0.20 to 1.40)	0.80 (0.40 to 2.00)	0.70 (0.20 to 1.50)	0.80 (0.20 to 1.90)	0.80 (0.20 to 1.80)	0.80 (0.20 to 1.80)
	Min to Max	26.1 to 104.2	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 5.8	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	256 (0)	253 (0)	422 (0)	218 (0)	241 (0)	318 (0)	1452 (0)	1134 (0)
	Caucasian	249 (97.3)	247 (97.6)	416 (98.6)	208 (95.4)	232 (96.3)	302 (95.0)	1405 (96.8)	1103 (97.3)
	Afro-Caribbean	4 (1.6)	4 (1.6)	5 (1.2)	5 (2.3)	4 (1.7)	6 (1.9)	24 (1.7)	18 (1.6)
	Asian (Not Chinese)	-	1 (0.4)	-	-	-	-	1 (0.1)	1 (0.1)

**Table 03 : Demographic Characteristics
Full Analysis Dataset : FRANCE**

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
	Mixed/Other	3 (1.2)	1 (0.4)	1 (0.2)	5 (2.3)	5 (2.1)	10 (3.1)	22 (1.5)	12 (1.1)
	Unknown	5	15	48	112	90	83	348	265
Region, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	Europe	261 (100.0)	268 (100.0)	470 (100.0)	330 (100.0)	331 (100.0)	401 (100.0)	1800 (100.0)	1399 (100.0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : FRANCE**

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	Internal Medicine	18 (6.9)	8 (3.0)	7 (1.5)	8 (2.4)	13 (3.9)	27 (6.7)	63 (3.5)	36 (2.6)
	Cardiology	197 (75.5)	193 (72.0)	348 (74.0)	240 (72.7)	260 (78.5)	276 (68.8)	1317 (73.2)	1041 (74.4)
	Neurology	28 (10.7)	44 (16.4)	103 (21.9)	65 (19.7)	37 (11.2)	68 (17.0)	317 (17.6)	249 (17.8)
	Geriatrics	2 (0.8)	1 (0.4)	2 (0.4)	1 (0.3)	2 (0.6)	3 (0.7)	9 (0.5)	6 (0.4)
	Primary Care/General Practice	16 (6.1)	22 (8.2)	10 (2.1)	16 (4.8)	19 (5.7)	27 (6.7)	94 (5.2)	67 (4.8)
Care Setting Location at Diagnosis, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	Hospital	110 (42.1)	123 (45.9)	319 (67.9)	238 (72.1)	221 (66.8)	285 (71.1)	1186 (65.9)	901 (64.4)
	Office	143 (54.8)	128 (47.8)	122 (26.0)	72 (21.8)	92 (27.8)	106 (26.4)	520 (28.9)	414 (29.6)
	Anticoagulation clinic/thrombosis centre	1 (0.4)	-	-	3 (0.9)	-	2 (0.5)	5 (0.3)	3 (0.2)
	Emergency room	7 (2.7)	17 (6.3)	29 (6.2)	17 (5.2)	18 (5.4)	8 (2.0)	89 (4.9)	81 (5.8)
Type of AF Diagnosed, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	Permanent	79 (30.3)	30 (11.2)	47 (10.0)	34 (10.3)	18 (5.4)	26 (6.5)	155 (8.6)	129 (9.2)
	Persistent	61 (23.4)	47 (17.5)	57 (12.1)	18 (5.5)	27 (8.2)	32 (8.0)	181 (10.1)	149 (10.7)
	Paroxysmal	92 (35.2)	93 (34.7)	134 (28.5)	103 (31.2)	100 (30.2)	117 (29.2)	547 (30.4)	430 (30.7)
	New	29 (11.1)	98 (36.6)	232 (49.4)	175 (53.0)	186 (56.2)	226 (56.4)	917 (50.9)	691 (49.4)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : FRANCE**

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Treatment Costs, n(%)	n (missing)	3 (0)	1 (2)	289 (0)	271 (0)	274 (0)	321 (0)	1156 (2)	835 (2)
	Public insurance	-	1 (100.0)	205 (70.9)	107 (39.5)	79 (28.8)	96 (29.9)	488 (42.2)	392 (46.9)
	Private (insurance)	-	-	-	-	-	1 (0.3)	1 (0.1)	-
	Combination	3 (100.0)	-	84 (29.1)	164 (60.5)	195 (71.2)	224 (69.8)	667 (57.7)	443 (53.1)
	Unknown	258	265	181	59	57	80	642	562
Treatment Sector, n(%)	n (missing)	5 (0)	1 (2)	352 (0)	302 (0)	331 (0)	400 (0)	1386 (2)	986 (2)
	In the public sector	4 (80.0)	-	262 (74.4)	231 (76.5)	217 (65.6)	277 (69.3)	987 (71.2)	710 (72.0)
	In the private sector	1 (20.0)	1 (100.0)	90 (25.6)	71 (23.5)	114 (34.4)	123 (30.8)	399 (28.8)	276 (28.0)
	Unknown	256	265	118	28	-	1	412	411

**Table 05 : Vital signs and life style
Full Analysis Dataset : FRANCE**

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Height (cm)	n (missing)	229 (32)	242 (26)	408 (62)	239 (91)	236 (95)	270 (131)	1395 (405)	1125 (274)
	Mean (SD)	167.1 (8.6)	167.8 (9.2)	167.6 (9.2)	168.4 (9.1)	168.5 (8.9)	167.5 (9.6)	167.9 (9.2)	168.0 (9.1)
	Median (IQR)	168.0 (160.0 to 173.0)	168.0 (160.0 to 175.0)	168.0 (160.5 to 175.0)	170.0 (162.0 to 175.0)	169.5 (162.0 to 176.0)	167.0 (160.0 to 175.0)	168.0 (161.0 to 175.0)	168.0 (162.0 to 175.0)
	Min to Max	147 to 193	140 to 198	135 to 198	140 to 188	144 to 187	145 to 195	135 to 198	135 to 198
Weight (kg)	n (missing)	229 (32)	242 (26)	408 (62)	239 (91)	236 (95)	270 (131)	1395 (405)	1125 (274)
	Mean (SD)	75.5 (16.4)	75.3 (16.1)	75.8 (15.4)	76.3 (18.0)	76.6 (17.0)	74.2 (16.5)	75.6 (16.5)	76.0 (16.5)
	Median (IQR)	74.0 (66.0 to 84.0)	75.0 (65.0 to 85.0)	75.0 (65.0 to 84.0)	75.0 (65.0 to 85.0)	75.0 (65.0 to 85.0)	73.0 (63.0 to 83.0)	75.0 (65.0 to 85.0)	75.0 (65.0 to 85.0)
	Min to Max	34 to 150	32 to 140	45 to 150	35 to 158	39 to 151	39 to 136	32 to 158	32 to 158
BMI (kg/m ²)	n (missing)	229 (32)	242 (26)	408 (62)	239 (91)	236 (95)	270 (131)	1395 (405)	1125 (274)
	Mean (SD)	27.0 (5.1)	26.7 (5.3)	27.0 (4.9)	26.8 (5.5)	27.0 (5.2)	26.4 (5.1)	26.8 (5.1)	26.9 (5.1)
	Median (IQR)	26.0 (24.0 to 29.0)	26.0 (24.0 to 29.0)	26.0 (24.0 to 30.0)	26.0 (23.0 to 29.0)	26.0 (24.0 to 29.0)	26.0 (23.0 to 29.0)	26.0 (24.0 to 29.0)	26.0 (24.0 to 29.0)
	Min to Max	13 to 47	11 to 51	18 to 45	13 to 57	16 to 47	16 to 47	11 to 57	11 to 57
BMI Category, n(%)	n (missing)	229 (32)	242 (26)	408 (62)	239 (91)	236 (95)	270 (131)	1395 (405)	1125 (274)
	<19	5 (2.2)	11 (4.5)	11 (2.7)	8 (3.3)	8 (3.4)	6 (2.2)	44 (3.2)	38 (3.4)
	19-<25	84 (36.7)	78 (32.2)	137 (33.6)	87 (36.4)	93 (39.4)	116 (43.0)	511 (36.6)	395 (35.1)
	25-<30	86 (37.6)	99 (40.9)	163 (40.0)	95 (39.7)	84 (35.6)	90 (33.3)	531 (38.1)	441 (39.2)
	30-<40	49 (21.4)	49 (20.2)	89 (21.8)	42 (17.6)	47 (19.9)	54 (20.0)	281 (20.1)	227 (20.2)
	>=40	5 (2.2)	5 (2.1)	8 (2.0)	7 (2.9)	4 (1.7)	4 (1.5)	28 (2.0)	24 (2.1)
Pulse (bpm)	n (missing)	227 (34)	260 (8)	460 (10)	289 (41)	311 (20)	380 (21)	1700 (100)	1320 (79)
	Mean (SD)	79.7 (23.6)	88.4 (28.3)	91.1 (27.3)	87.7 (25.3)	89.7 (25.9)	91.4 (28.4)	89.9 (27.1)	89.5 (26.8)
	Median (IQR)	74.0 (63.0 to 88.0)	82.0 (66.0 to 106.0)	85.0 (70.0 to 110.0)	81.0 (69.0 to 104.0)	85.0 (70.0 to 105.0)	85.0 (70.0 to 108.0)	84.0 (69.5 to 108.0)	84.0 (69.0 to 107.0)
	Min to Max	36 to 160	40 to 200	36 to 187	39 to 183	40 to 174	40 to 200	36 to 200	36 to 200

**Table 05 : Vital signs and life style
Full Analysis Dataset : FRANCE**

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Systolic BP (mm Hg)	n (missing)	241 (20)	258 (10)	460 (10)	306 (24)	309 (22)	366 (35)	1699 (101)	1333 (66)
	Mean (SD)	136.5 (17.7)	139.2 (19.7)	138.7 (20.6)	140.5 (21.5)	136.7 (22.6)	138.3 (21.9)	138.7 (21.3)	138.7 (21.1)
	Median (IQR)	135.0 (125.0 to 145.0)	140.0 (130.0 to 150.0)	140.0 (125.0 to 150.0)	140.0 (127.0 to 154.0)	138.0 (120.0 to 150.0)	136.0 (122.0 to 151.0)	140.0 (125.0 to 150.0)	140.0 (125.0 to 150.0)
	Min to Max	95 to 240	85 to 200	74 to 210	90 to 217	70 to 260	85 to 207	70 to 260	70 to 260
Diastolic BP (mm Hg)	n (missing)	241 (20)	258 (10)	460 (10)	306 (24)	309 (22)	366 (35)	1699 (101)	1333 (66)
	Mean (SD)	78.2 (10.3)	79.4 (12.2)	80.0 (14.1)	80.4 (12.6)	78.2 (13.8)	79.9 (13.5)	79.6 (13.4)	79.6 (13.3)
	Median (IQR)	80.0 (70.0 to 84.0)	80.0 (70.0 to 87.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 85.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 88.0)
	Min to Max	50 to 130	45 to 120	45 to 133	51 to 129	40 to 168	40 to 140	40 to 168	40 to 168
LVEF (%)	n (missing)	217 (44)	212 (56)	372 (98)	218 (112)	230 (101)	271 (130)	1303 (497)	1032 (367)
	Mean (SD)	60.8 (12.0)	60.8 (10.4)	58.6 (11.7)	57.0 (11.9)	58.3 (12.3)	58.7 (12.3)	58.7 (11.8)	58.6 (11.7)
	Median (IQR)	64.0 (58.0 to 69.0)	63.0 (55.0 to 68.0)	60.0 (50.5 to 65.0)	60.0 (50.0 to 65.0)	60.0 (50.0 to 65.0)	60.0 (52.0 to 65.0)	60.0 (52.0 to 66.0)	60.0 (52.0 to 66.0)
	Min to Max	20 to 81	25 to 83	20 to 88	15 to 85	20 to 81	15 to 81	15 to 88	15 to 88
LVEF Category, n (missing) n(%)	n (missing)	217 (44)	212 (56)	372 (98)	218 (112)	230 (101)	271 (130)	1303 (497)	1032 (367)
	<40%	13 (6.0)	8 (3.8)	28 (7.5)	18 (8.3)	18 (7.8)	22 (8.1)	94 (7.2)	72 (7.0)
	>=40%	204 (94.0)	204 (96.2)	344 (92.5)	200 (91.7)	212 (92.2)	249 (91.9)	1209 (92.8)	960 (93.0)
History of Hypertension, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	328 (0)	327 (0)	399 (0)	1792 (0)	1393 (0)
	No	69 (26.4)	71 (26.5)	123 (26.2)	97 (29.6)	93 (28.4)	121 (30.3)	505 (28.2)	384 (27.6)
	Yes	192 (73.6)	197 (73.5)	347 (73.8)	231 (70.4)	234 (71.6)	278 (69.7)	1287 (71.8)	1009 (72.4)

Table 05 : Vital signs and life style
Full Analysis Dataset : FRANCE

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
	Unknown	-	-	-	2	4	2	8	6
Alcohol Consumption, n(%)	n (missing)	244 (0)	241 (0)	399 (0)	254 (0)	253 (0)	281 (0)	1428 (0)	1147 (0)
	Abstinent	140 (57.4)	141 (58.5)	253 (63.4)	138 (54.3)	142 (56.1)	187 (66.5)	861 (60.3)	674 (58.8)
	Light	70 (28.7)	64 (26.6)	95 (23.8)	70 (27.6)	61 (24.1)	73 (26.0)	363 (25.4)	290 (25.3)
	Moderate	28 (11.5)	29 (12.0)	40 (10.0)	38 (15.0)	37 (14.6)	13 (4.6)	157 (11.0)	144 (12.6)
	Heavy	6 (2.5)	7 (2.9)	11 (2.8)	8 (3.1)	13 (5.1)	8 (2.8)	47 (3.3)	39 (3.4)
	Unknown	17	27	71	76	78	120	372	252
Smoker, n(%)	n (missing)	255 (0)	255 (0)	432 (0)	297 (0)	290 (0)	335 (0)	1609 (0)	1274 (0)
	No	182 (71.4)	174 (68.2)	294 (68.1)	186 (62.6)	179 (61.7)	229 (68.4)	1062 (66.0)	833 (65.4)
	Ex-smoker	60 (23.5)	56 (22.0)	92 (21.3)	81 (27.3)	76 (26.2)	78 (23.3)	383 (23.8)	305 (23.9)
	Current smoker	13 (5.1)	25 (9.8)	46 (10.6)	30 (10.1)	35 (12.1)	28 (8.4)	164 (10.2)	136 (10.7)
	Unknown	6	13	38	33	41	66	191	125

Table 06 : Clinical History
Full Analysis Dataset : FRANCE

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Congestive heart failure, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	No	237 (90.8)	246 (91.8)	397 (84.5)	292 (88.5)	306 (92.4)	364 (90.8)	1605 (89.2)	1241 (88.7)
	Yes	24 (9.2)	22 (8.2)	73 (15.5)	38 (11.5)	25 (7.6)	37 (9.2)	195 (10.8)	158 (11.3)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	23 (237)	22 (246)	71 (397)	37 (292)	22 (306)	32 (364)	184 (1605)	152 (1241)
	I	-	2 (9.1)	2 (2.8)	1 (2.7)	-	2 (6.3)	7 (3.8)	5 (3.3)
	II	11 (47.8)	11 (50.0)	35 (49.3)	21 (56.8)	13 (59.1)	18 (56.3)	98 (53.3)	80 (52.6)
	III	12 (52.2)	8 (36.4)	32 (45.1)	15 (40.5)	9 (40.9)	9 (28.1)	73 (39.7)	64 (42.1)
	IV	-	1 (4.5)	2 (2.8)	-	-	3 (9.4)	6 (3.3)	3 (2.0)
	Unknown	1	-	2	1	3	5	11	6
Coronary artery disease, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	No	223 (85.4)	226 (84.3)	397 (84.5)	291 (88.2)	284 (85.8)	341 (85.0)	1539 (85.5)	1198 (85.6)
	Yes	38 (14.6)	42 (15.7)	73 (15.5)	39 (11.8)	47 (14.2)	60 (15.0)	261 (14.5)	201 (14.4)
Acute coronary syndrome, n(%)	n (missing)	261 (0)	268 (0)	467 (0)	328 (0)	330 (0)	399 (0)	1792 (0)	1393 (0)
	No	231 (88.5)	245 (91.4)	418 (89.5)	300 (91.5)	295 (89.4)	360 (90.2)	1618 (90.3)	1258 (90.3)
	Yes	30 (11.5)	23 (8.6)	49 (10.5)	28 (8.5)	35 (10.6)	39 (9.8)	174 (9.7)	135 (9.7)
	Unknown	-	-	3	2	1	2	8	6
Carotid Occlusive Disease, n(%)	n (missing)	261 (0)	268 (0)	466 (0)	329 (0)	329 (0)	396 (0)	1788 (0)	1392 (0)
	No	256 (98.1)	258 (96.3)	444 (95.3)	316 (96.0)	309 (93.9)	382 (96.5)	1709 (95.6)	1327 (95.3)

Table 06 : Clinical History
Full Analysis Dataset : FRANCE

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
	Yes	5 (1.9)	10 (3.7)	22 (4.7)	13 (4.0)	20 (6.1)	14 (3.5)	79 (4.4)	65 (4.7)
	Unknown	-	-	4	1	2	5	12	7
PE or DVT, n(%)	n (missing)	261 (0)	268 (0)	466 (0)	328 (0)	330 (0)	400 (0)	1792 (0)	1392 (0)
	No	249 (95.4)	251 (93.7)	442 (94.8)	302 (92.1)	302 (91.5)	388 (97.0)	1685 (94.0)	1297 (93.2)
	Yes	12 (4.6)	17 (6.3)	24 (5.2)	26 (7.9)	28 (8.5)	12 (3.0)	107 (6.0)	95 (6.8)
	Unknown	-	-	4	2	1	1	8	7
Other Thromboemboli sm, n(%)	n (missing)	260 (1)	268 (0)	451 (19)	0 (330)	0 (331)	0 (401)	719 (1081)	719 (680)
	No	257 (98.8)	265 (98.9)	446 (98.9)	-	-	-	711 (98.9)	711 (98.9)
	Yes	3 (1.2)	3 (1.1)	5 (1.1)	-	-	-	8 (1.1)	8 (1.1)
Systemic Embolization, n(%)	n (missing)	261 (0)	268 (0)	466 (0)	326 (0)	329 (0)	400 (0)	1789 (0)	1389 (0)
	No	260 (99.6)	266 (99.3)	462 (99.1)	325 (99.7)	329 (100.0)	400 (100.0)	1782 (99.6)	1382 (99.5)
	Yes	1 (0.4)	2 (0.7)	4 (0.9)	1 (0.3)	-	-	7 (0.4)	7 (0.5)
	Unknown	-	-	4	4	2	1	11	10
Coronary Artery Bypass Graft, n(%)	n (missing)	249 (0)	256 (0)	465 (0)	329 (0)	329 (0)	399 (0)	1778 (0)	1379 (0)
	No	243 (97.6)	249 (97.3)	450 (96.8)	317 (96.4)	317 (96.4)	388 (97.2)	1721 (96.8)	1333 (96.7)
	Yes	6 (2.4)	7 (2.7)	15 (3.2)	12 (3.6)	12 (3.6)	11 (2.8)	57 (3.2)	46 (3.3)
	Unknown	12	12	5	1	2	2	22	20
Stroke/TIA, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)

Table 06 : Clinical History
Full Analysis Dataset : FRANCE

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
	No	210 (80.5)	201 (75.0)	341 (72.6)	261 (79.1)	275 (83.1)	329 (82.0)	1407 (78.2)	1078 (77.1)
	Yes	51 (19.5)	67 (25.0)	129 (27.4)	69 (20.9)	56 (16.9)	72 (18.0)	393 (21.8)	321 (22.9)
Stroke, n(%)	n (missing)	261 (0)	268 (0)	466 (0)	330 (0)	328 (0)	400 (0)	1792 (0)	1392 (0)
	No	219 (83.9)	212 (79.1)	368 (79.0)	284 (86.1)	292 (89.0)	347 (86.8)	1503 (83.9)	1156 (83.0)
	Yes	42 (16.1)	56 (20.9)	98 (21.0)	46 (13.9)	36 (11.0)	53 (13.3)	289 (16.1)	236 (17.0)
	Unknown	-	-	4	-	3	1	8	7
History of Bleeding, n(%)	n (missing)	261 (0)	268 (0)	464 (0)	330 (0)	328 (0)	400 (0)	1790 (0)	1390 (0)
	No	255 (97.7)	261 (97.4)	444 (95.7)	311 (94.2)	311 (94.8)	385 (96.3)	1712 (95.6)	1327 (95.5)
	Yes	6 (2.3)	7 (2.6)	20 (4.3)	19 (5.8)	17 (5.2)	15 (3.8)	78 (4.4)	63 (4.5)
	Unknown	-	-	6	-	3	1	10	9
Hypercholester olaemia, n(%)	n (missing)	261 (0)	268 (0)	469 (0)	321 (0)	326 (0)	392 (0)	1776 (0)	1384 (0)
	No	139 (53.3)	144 (53.7)	284 (60.6)	208 (64.8)	196 (60.1)	263 (67.1)	1095 (61.7)	832 (60.1)
	Yes	122 (46.7)	124 (46.3)	185 (39.4)	113 (35.2)	130 (39.9)	129 (32.9)	681 (38.3)	552 (39.9)
	Unknown	-	-	1	9	5	9	24	15
Diabetes, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	No	227 (87.0)	221 (82.5)	401 (85.3)	277 (83.9)	259 (78.2)	324 (80.8)	1482 (82.3)	1158 (82.8)
	Type I	4 (1.5)	5 (1.9)	6 (1.3)	6 (1.8)	3 (0.9)	1 (0.2)	21 (1.2)	20 (1.4)
	Type II	30 (11.5)	42 (15.7)	63 (13.4)	47 (14.2)	69 (20.8)	76 (19.0)	297 (16.5)	221 (15.8)
Diabetes, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	No	227 (87.0)	221 (82.5)	401 (85.3)	277 (83.9)	259 (78.2)	324 (80.8)	1482 (82.3)	1158 (82.8)
	Yes	34 (13.0)	47 (17.5)	69 (14.7)	53 (16.1)	72 (21.8)	77 (19.2)	318 (17.7)	241 (17.2)
Cirrhosis, n(%)	n (missing)	261 (0)	268 (0)	465 (0)	321 (0)	325 (0)	398 (0)	1777 (0)	1379 (0)
	No	258 (98.9)	268 (100.0)	465 (100.0)	319 (99.4)	325 (100.0)	398 (100.0)	1775 (99.9)	1377 (99.9)

Table 06 : Clinical History
Full Analysis Dataset : FRANCE

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
	Yes	3 (1.1)	-	-	2 (0.6)	-	-	2 (0.1)	2 (0.1)
	Unknown	-	-	5	9	6	3	23	20
Dementia, n(%)	n (missing)	261 (0)	268 (0)	466 (0)	327 (0)	328 (0)	399 (0)	1788 (0)	1389 (0)
	No	257 (98.5)	264 (98.5)	460 (98.7)	321 (98.2)	324 (98.8)	388 (97.2)	1757 (98.3)	1369 (98.6)
	Yes	4 (1.5)	4 (1.5)	6 (1.3)	6 (1.8)	4 (1.2)	11 (2.8)	31 (1.7)	20 (1.4)
	Unknown	-	-	4	3	3	2	12	10
Hyperthyroidis m, n(%)	n (missing)	261 (0)	268 (0)	468 (0)	317 (0)	330 (0)	393 (0)	1776 (0)	1383 (0)
	No	256 (98.1)	263 (98.1)	464 (99.1)	315 (99.4)	324 (98.2)	389 (99.0)	1755 (98.8)	1366 (98.8)
	Yes	5 (1.9)	5 (1.9)	4 (0.9)	2 (0.6)	6 (1.8)	4 (1.0)	21 (1.2)	17 (1.2)
	Unknown	-	-	2	13	1	8	24	16
Hypothyroidism, n (missing) n(%)	n (missing)	261 (0)	268 (0)	468 (0)	318 (0)	329 (0)	392 (0)	1775 (0)	1383 (0)
	No	235 (90.0)	252 (94.0)	433 (92.5)	296 (93.1)	309 (93.9)	369 (94.1)	1659 (93.5)	1290 (93.3)
	Yes	26 (10.0)	16 (6.0)	35 (7.5)	22 (6.9)	20 (6.1)	23 (5.9)	116 (6.5)	93 (6.7)
	Unknown	-	-	2	12	2	9	25	16
Vascular Disease, n(%)	n (missing)	261 (0)	268 (0)	467 (3)	330 (0)	331 (0)	400 (1)	1796 (4)	1396 (3)
	No	213 (81.6)	225 (84.0)	390 (83.5)	280 (84.8)	275 (83.1)	337 (84.3)	1507 (83.9)	1170 (83.8)
	Yes	48 (18.4)	43 (16.0)	77 (16.5)	50 (15.2)	56 (16.9)	63 (15.8)	289 (16.1)	226 (16.2)
Moderate to Severe CKD, n(%)	n (missing)	261 (0)	268 (0)	470 (0)	330 (0)	331 (0)	401 (0)	1800 (0)	1399 (0)
	No	240 (92.0)	243 (90.7)	421 (89.6)	286 (86.7)	287 (86.7)	333 (83.0)	1570 (87.2)	1237 (88.4)
	Yes	21 (8.0)	25 (9.3)	49 (10.4)	44 (13.3)	44 (13.3)	68 (17.0)	230 (12.8)	162 (11.6)

Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

Table 06 : Clinical History
Full Analysis Dataset : FRANCE

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : FRANCE**

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Baseline Treatment, n(%)	n (missing)	256 (0)	265 (0)	458 (0)	328 (0)	328 (0)	401 (0)	1780 (0)	1379 (0)
	VKA	141 (55.1)	144 (54.3)	152 (33.2)	95 (29.0)	89 (27.1)	66 (16.5)	546 (30.7)	480 (34.8)
	VKA+AP	51 (19.9)	52 (19.6)	64 (14.0)	21 (6.4)	17 (5.2)	21 (5.2)	175 (9.8)	154 (11.2)
	FXA	3 (1.2)	2 (0.8)	57 (12.4)	78 (23.8)	129 (39.3)	195 (48.6)	461 (25.9)	266 (19.3)
	FXA+AP	2 (0.8)	1 (0.4)	14 (3.1)	16 (4.9)	13 (4.0)	21 (5.2)	65 (3.7)	44 (3.2)
	DTI	-	-	65 (14.2)	36 (11.0)	21 (6.4)	11 (2.7)	133 (7.5)	122 (8.8)
	DTI+AP	-	-	14 (3.1)	7 (2.1)	1 (0.3)	2 (0.5)	24 (1.3)	22 (1.6)
	AP	54 (21.1)	57 (21.5)	63 (13.8)	41 (12.5)	22 (6.7)	43 (10.7)	226 (12.7)	183 (13.3)
	NONE	5 (2.0)	9 (3.4)	29 (6.3)	34 (10.4)	36 (11.0)	42 (10.5)	150 (8.4)	108 (7.8)
	Unknown	5	3	12	2	3	-	20	20
	VKA±AP	192 (75.0)	196 (74.0)	216 (47.2)	116 (35.4)	106 (32.3)	87 (21.7)	721 (40.5)	634 (46.0)
	FXA±AP	5 (2.0)	3 (1.1)	71 (15.5)	94 (28.7)	142 (43.3)	216 (53.9)	526 (29.6)	310 (22.5)
	DTI±AP	-	-	79 (17.2)	43 (13.1)	22 (6.7)	13 (3.2)	157 (8.8)	144 (10.4)
	FXA/DTI	3 (1.2)	2 (0.8)	122 (26.6)	114 (34.8)	150 (45.7)	206 (51.4)	594 (33.4)	388 (28.1)
	FXA/DTI+AP	2 (0.8)	1 (0.4)	28 (6.1)	23 (7.0)	14 (4.3)	23 (5.7)	89 (5.0)	66 (4.8)
	FXA/DTI±AP	5 (2.0)	3 (1.1)	150 (32.8)	137 (41.8)	164 (50.0)	229 (57.1)	683 (38.4)	454 (32.9)
	AC	144 (56.3)	146 (55.1)	274 (59.8)	209 (63.7)	239 (72.9)	272 (67.8)	1140 (64.0)	868 (62.9)
	AC+AP	53 (20.7)	53 (20.0)	92 (20.1)	44 (13.4)	31 (9.5)	44 (11.0)	264 (14.8)	220 (16.0)
	AC±AP	197 (77.0)	199 (75.1)	366 (79.9)	253 (77.1)	270 (82.3)	316 (78.8)	1404 (78.9)	1088 (78.9)

Table 08: Treatment
Full Analysis Dataset : FRANCE

	Cohort 1 Retrospective (N=261) (n %)	Cohort 1 Prospective (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
Anti-platelet (non mutually exclusive groups)								
Glycoprotein inhibitors	-	1 (0.4)	1 (0.2)	1 (0.3)	-	-	3 (0.2)	3 (0.2)
ADP receptor/P2Y12 inhibitors	20 (7.7)	12 (4.5)	35 (7.4)	11 (3.3)	11 (3.3)	14 (3.5)	83 (4.6)	69 (4.9)
Prostaglandin Cox inhibitors	-	-	1 (0.2)	2 (0.6)	-	-	3 (0.2)	3 (0.2)
ASA	9 (3.4)	21 (7.8)	-	17 (5.2)	5 (1.5)	2 (0.5)	45 (2.5)	43 (3.1)
	71 (27.2)	76 (28.4)	127 (27.0)	56 (17.0)	40 (12.1)	80 (20.0)	379 (21.1)	299 (21.4)
Anticoagulant drugs (non mutually exclusive groups)								
VKA	195 (74.7)	199 (74.3)	224 (47.7)	117 (35.5)	108 (32.6)	87 (21.7)	735 (40.8)	648 (46.3)
FXa	8 (3.1)	6 (2.2)	83 (17.7)	96 (29.1)	144 (43.5)	216 (53.9)	545 (30.3)	329 (23.5)
DTI	-	-	83 (17.7)	45 (13.6)	22 (6.6)	13 (3.2)	163 (9.1)	150 (10.7)
Heparinoid	2 (0.8)	13 (4.9)	7 (1.5)	5 (1.5)	4 (1.2)	3 (0.7)	32 (1.8)	29 (2.1)
Heparins	12 (4.6)	20 (7.5)	108 (23.0)	42 (12.7)	28 (8.5)	22 (5.5)	220 (12.2)	198 (14.2)
Other	-	-	4 (0.9)	3 (0.9)	-	1 (0.2)	8 (0.4)	7 (0.5)

Table 09 : Risk scores
Full Analysis Dataset : FRANCE

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
CHADS2 Score	n (missing)	253 (8)	265 (3)	466 (4)	317 (13)	318 (13)	386 (15)	1752 (48)	1366 (33)
	Mean (SD)	2.0 (1.1)	2.1 (1.2)	2.3 (1.2)	2.1 (1.2)	1.9 (1.2)	2.1 (1.2)	2.1 (1.2)	2.1 (1.2)
	Median (IQR)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)
	Min to Max	0 to 6	0 to 6	0 to 6	0 to 5	0 to 5	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	253 (8)	265 (3)	466 (4)	317 (13)	318 (13)	386 (15)	1752 (48)	1366 (33)
	0	12 (4.7)	16 (6.0)	29 (6.2)	23 (7.3)	29 (9.1)	27 (7.0)	124 (7.1)	97 (7.1)
	1	80 (31.6)	70 (26.4)	106 (22.7)	81 (25.6)	92 (28.9)	101 (26.2)	450 (25.7)	349 (25.5)
	2	98 (38.7)	92 (34.7)	152 (32.6)	113 (35.6)	113 (35.5)	141 (36.5)	611 (34.9)	470 (34.4)
	3	31 (12.3)	47 (17.7)	92 (19.7)	50 (15.8)	42 (13.2)	64 (16.6)	295 (16.8)	231 (16.9)
	4	28 (11.1)	32 (12.1)	70 (15.0)	42 (13.2)	34 (10.7)	39 (10.1)	217 (12.4)	178 (13.0)
	5	3 (1.2)	7 (2.6)	16 (3.4)	8 (2.5)	8 (2.5)	13 (3.4)	52 (3.0)	39 (2.9)
	6	1 (0.4)	1 (0.4)	1 (0.2)	-	-	1 (0.3)	3 (0.2)	2 (0.1)
CHA2DS2- VASc Score	n (missing)	253 (8)	265 (3)	463 (7)	316 (14)	318 (13)	386 (15)	1748 (52)	1362 (37)
	Mean (SD)	3.5 (1.6)	3.6 (1.5)	3.7 (1.6)	3.5 (1.6)	3.4 (1.6)	3.6 (1.5)	3.6 (1.6)	3.6 (1.6)
	Median (IQR)	3.0 (2.0 to 5.0)	4.0 (3.0 to 5.0)	4.0 (3.0 to 5.0)	4.0 (2.0 to 5.0)	3.0 (2.0 to 4.0)	4.0 (3.0 to 4.0)	4.0 (3.0 to 5.0)	4.0 (3.0 to 5.0)
	Min to Max	0 to 7	0 to 7	0 to 7	0 to 8	0 to 7	0 to 8	0 to 8	0 to 8
CHA2DS2- VASc score categories, n(%)	n (missing)	253 (8)	265 (3)	463 (7)	316 (14)	318 (13)	386 (15)	1748 (52)	1362 (37)
	0	4 (1.6)	5 (1.9)	11 (2.4)	12 (3.8)	7 (2.2)	6 (1.6)	41 (2.3)	35 (2.6)
	1	24 (9.5)	23 (8.7)	41 (8.9)	21 (6.6)	32 (10.1)	30 (7.8)	147 (8.4)	117 (8.6)
	2	37 (14.6)	32 (12.1)	51 (11.0)	48 (15.2)	50 (15.7)	53 (13.7)	234 (13.4)	181 (13.3)
	3	62 (24.5)	58 (21.9)	91 (19.7)	75 (23.7)	85 (26.7)	90 (23.3)	399 (22.8)	309 (22.7)
	4	61 (24.1)	78 (29.4)	124 (26.8)	70 (22.2)	70 (22.0)	111 (28.8)	453 (25.9)	342 (25.1)

Table 09 : Risk scores
Full Analysis Dataset : FRANCE

Variable	Statistics	Cohort 1 Retrospective patients (N=261) (n %)	Cohort 1 Prospective patients (N=268) (n %)	Cohort 2 (N=470) (n %)	Cohort 3 (N=330) (n %)	Cohort 4 (N=331) (n %)	Cohort 5 (N=401) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1800)	Total Prospective patients Cohorts 1 to 4 (N=1399)
	5	34 (13.4)	35 (13.2)	77 (16.6)	50 (15.8)	34 (10.7)	51 (13.2)	247 (14.1)	196 (14.4)
	6-9	31 (12.3)	34 (12.8)	68 (14.7)	40 (12.7)	40 (12.6)	45 (11.7)	227 (13.0)	182 (13.4)
HAS-BLED score	n (missing)	194 (67)	191 (77)	325 (145)	235 (95)	222 (109)	253 (148)	1226 (574)	973 (426)
	Mean (SD)	1.6 (0.8)	1.8 (0.9)	1.6 (1.0)	1.7 (1.0)	1.5 (0.9)	1.6 (1.0)	1.7 (1.0)	1.7 (0.9)
	Median (IQR)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 4	0 to 5	0 to 5	0 to 4	0 to 6	0 to 6	0 to 5
HAS-BLED score categories, n(%)	n (missing)	194 (67)	191 (77)	325 (145)	235 (95)	222 (109)	253 (148)	1226 (574)	973 (426)
	0	12 (6.2)	6 (3.1)	38 (11.7)	22 (9.4)	16 (7.2)	22 (8.7)	104 (8.5)	82 (8.4)
	1	81 (41.8)	69 (36.1)	112 (34.5)	81 (34.5)	112 (50.5)	106 (41.9)	480 (39.2)	374 (38.4)
	2	76 (39.2)	79 (41.4)	122 (37.5)	87 (37.0)	61 (27.5)	79 (31.2)	428 (34.9)	349 (35.9)
	3	21 (10.8)	31 (16.2)	45 (13.8)	33 (14.0)	28 (12.6)	36 (14.2)	173 (14.1)	137 (14.1)
	4	4 (2.1)	6 (3.1)	6 (1.8)	11 (4.7)	5 (2.3)	9 (3.6)	37 (3.0)	28 (2.9)
	5	-	-	2 (0.6)	1 (0.4)	-	-	3 (0.2)	3 (0.3)
	6-9	-	-	-	-	-	1 (0.4)	1 (0.1)	-

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : FRANCE**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	1	25	2	50	-	-	-	-	-	-	-	-	1	25	-	-	-
	1	15	62.5	3	12.5	2	8.3	-	-	-	-	-	-	4	16.7	-	-	-
	2	22	59.5	4	10.8	-	-	1	2.7	-	-	-	-	8	21.6	2	5.4	-
	3	35	58.3	10	16.7	-	-	-	-	-	-	-	-	15	25	-	-	2
	4	34	56.7	15	25	-	-	-	-	-	-	-	-	10	16.7	1	1.7	1
	5	16	47.1	8	23.5	1	2.9	1	2.9	-	-	-	-	7	20.6	1	2.9	-
6-9	14	48.3	8	27.6	-	-	-	-	-	-	-	-	7	24.1	-	-	2	
Cohort 1 prospective	0	3	60	-	-	-	-	-	-	-	-	-	-	2	40	-	-	-
	1	13	56.5	1	4.3	-	-	-	-	-	-	-	-	7	30.4	2	8.7	-
	2	15	46.9	7	21.9	-	-	-	-	-	-	-	-	9	28.1	1	3.1	-
	3	30	51.7	9	15.5	-	-	-	-	-	-	-	-	15	25.9	4	6.9	-
	4	44	57.9	14	18.4	-	-	1	1.3	-	-	-	-	17	22.4	-	-	2
	5	19	55.9	10	29.4	-	-	-	-	-	-	-	-	3	8.8	2	5.9	1
6-9	18	52.9	10	29.4	2	5.9	-	-	-	-	-	-	4	11.8	-	-	-	
Cohort 2	0	5	50	-	-	1	10	-	-	2	20	1	10	-	-	1	10	1
	1	13	33.3	4	10.3	5	12.8	1	2.6	2	5.1	-	-	7	17.9	7	17.9	2
	2	11	22	6	12	8	16	2	4	10	20	2	4	8	16	3	6	1
	3	35	39.3	10	11.2	9	10.1	2	2.2	14	15.7	3	3.4	10	11.2	6	6.7	2
	4	45	37.2	20	16.5	12	9.9	3	2.5	13	10.7	4	3.3	18	14.9	6	5	3
	5	25	33.3	11	14.7	10	13.3	-	-	15	20	2	2.7	9	12	3	4	2
6-9	18	26.9	12	17.9	11	16.4	6	9	7	10.4	1	1.5	9	13.4	3	4.5	1	
Cohort 3	0	1	8.3	-	-	4	33.3	-	-	3	25	-	-	1	8.3	3	25	-
	1	3	14.3	-	-	7	33.3	1	4.8	3	14.3	1	4.8	2	9.5	4	19	-
	2	11	22.9	4	8.3	17	35.4	2	4.2	5	10.4	3	6.3	4	8.3	2	4.2	-
	3	18	24.3	5	6.8	19	25.7	3	4.1	9	12.2	-	-	15	20.3	5	6.8	1
4	20	28.6	5	7.1	14	20	3	4.3	10	14.3	2	2.9	8	11.4	8	11.4	-	

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : FRANCE**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	5	18	36.7	3	6.1	9	18.4	4	8.2	3	6.1	-	-	9	18.4	3	6.1	1
	6-9	17	42.5	4	10	7	17.5	3	7.5	1	2.5	1	2.5	2	5	5	12.5	-
Cohort 4	0	2	28.6	-	-	3	42.9	-	-	-	-	-	-	-	-	2	28.6	-
	1	4	12.5	-	-	9	28.1	-	-	2	6.3	-	-	7	21.9	10	31.3	-
	2	10	20	-	-	28	56	2	4	4	8	-	-	1	2	5	10	-
	3	19	22.4	4	4.7	38	44.7	5	5.9	6	7.1	1	1.2	3	3.5	9	10.6	-
	4	22	31.4	5	7.1	24	34.3	4	5.7	6	8.6	-	-	4	5.7	5	7.1	-
	5	14	41.2	1	2.9	12	35.3	1	2.9	1	2.9	-	-	3	8.8	2	5.9	-
	6-9	14	35.9	5	12.8	11	28.2	1	2.6	1	2.6	-	-	4	10.3	3	7.7	1
Cohort 5	0	1	16.7	-	-	5	83.3	-	-	-	-	-	-	-	-	-	-	-
	1	7	23.3	1	3.3	13	43.3	-	-	-	-	-	-	5	16.7	4	13.3	-
	2	3	5.7	1	1.9	33	62.3	2	3.8	2	3.8	1	1.9	5	9.4	6	11.3	-
	3	11	12.2	6	6.7	46	51.1	7	7.8	2	2.2	-	-	10	11.1	8	8.9	-
	4	22	19.8	4	3.6	52	46.8	8	7.2	3	2.7	1	0.9	13	11.7	8	7.2	-
	5	14	27.5	3	5.9	21	41.2	3	5.9	2	3.9	-	-	2	3.9	6	11.8	-
	6-9	8	17.8	5	11.1	18	40	1	2.2	2	4.4	-	-	4	8.9	7	15.6	-
Total Prospective patients Cohorts 1 to 5	0	12	30	-	-	13	32.5	-	-	5	12.5	1	2.5	3	7.5	6	15	1
	1	40	27.6	6	4.1	34	23.4	2	1.4	7	4.8	1	0.7	28	19.3	27	18.6	2
	2	50	21.5	18	7.7	86	36.9	8	3.4	21	9	6	2.6	27	11.6	17	7.3	1
	3	113	28.5	34	8.6	112	28.3	17	4.3	31	7.8	4	1	53	13.4	32	8.1	3
	4	153	34.2	48	10.7	102	22.8	19	4.2	32	7.1	7	1.6	60	13.4	27	6	5
	5	90	37	28	11.5	52	21.4	8	3.3	21	8.6	2	0.8	26	10.7	16	6.6	4
	6-9	75	33.3	36	16	49	21.8	11	4.9	11	4.9	2	0.9	23	10.2	18	8	2

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : FRANCE**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total	0	11	32.4	-	-	8	23.5	-	-	5	14.7	1	2.9	3	8.8	6	17.6	1
Prospective patients																		
Cohorts 1 to 4																		
	1	33	28.7	5	4.3	21	18.3	2	1.7	7	6.1	1	0.9	23	20	23	20	2
	2	47	26.1	17	9.4	53	29.4	6	3.3	19	10.6	5	2.8	22	12.2	11	6.1	1
	3	102	33.3	28	9.2	66	21.6	10	3.3	29	9.5	4	1.3	43	14.1	24	7.8	3
	4	131	38.9	44	13.1	50	14.8	11	3.3	29	8.6	6	1.8	47	13.9	19	5.6	5
	5	76	39.6	25	13	31	16.1	5	2.6	19	9.9	2	1	24	12.5	10	5.2	4
	6-9	67	37.2	31	17.2	31	17.2	10	5.6	9	5	2	1.1	19	10.6	11	6.1	2

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : FRANCE**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 1 retrospective	0	10	83.3	-	-	2	16.7	-	-	-	-	-	-	-	-	-	-	-	-
	1	68	87.2	3	3.8	-	-	1	1.3	-	-	-	-	4	5.1	2	2.6	3	
	2	17	22.7	30	40	1	1.3	-	-	-	-	-	-	26	34.7	1	1.3	1	
	3	7	33.3	8	38.1	-	-	1	4.8	-	-	-	-	5	23.8	-	-	-	
	4-9	-	-	1	25	-	-	-	-	-	-	-	-	3	75	-	-	-	
Cohort 1 prospective	0	5	83.3	-	-	-	-	-	-	-	-	-	-	-	-	1	16.7	-	
	1	54	79.4	2	2.9	1	1.5	-	-	-	-	-	-	8	11.8	3	4.4	1	
	2	26	32.9	20	25.3	-	-	1	1.3	-	-	-	-	31	39.2	1	1.3	-	
	3	12	40	9	30	-	-	-	-	-	-	-	-	9	30	-	-	1	
	4-9	1	16.7	4	66.7	-	-	-	-	-	-	-	-	1	16.7	-	-	-	
Cohort 2	0	16	45.7	-	-	9	25.7	-	-	4	11.4	-	-	-	-	6	17.1	3	
	1	52	48.1	4	3.7	15	13.9	2	1.9	17	15.7	1	0.9	7	6.5	10	9.3	4	
	2	36	29.8	29	24	12	9.9	4	3.3	8	6.6	4	3.3	24	19.8	4	3.3	1	
	3	5	11.1	12	26.7	5	11.1	4	8.9	6	13.3	2	4.4	9	20	2	4.4	-	
	4-9	2	25	1	12.5	1	12.5	1	12.5	-	-	-	-	3	37.5	-	-	-	
Cohort 3	0	1	4.8	-	-	11	52.4	-	-	5	23.8	-	-	-	-	4	19	1	
	1	29	36.3	1	1.3	26	32.5	1	1.3	14	17.5	1	1.3	1	1.3	7	8.8	1	
	2	22	25.3	8	9.2	18	20.7	4	4.6	7	8	3	3.4	18	20.7	7	8	-	
	3	10	30.3	1	3	3	9.1	3	9.1	2	6.1	2	6.1	5	15.2	7	21.2	-	
	4-9	1	8.3	2	16.7	1	8.3	4	33.3	-	-	-	-	2	16.7	2	16.7	-	
Cohort 4	0	1	6.3	-	-	10	62.5	-	-	2	12.5	-	-	-	-	3	18.8	-	
	1	35	31.3	-	-	52	46.4	2	1.8	11	9.8	-	-	3	2.7	9	8	-	
	2	21	34.4	4	6.6	22	36.1	7	11.5	1	1.6	1	1.6	3	4.9	2	3.3	-	
	3	5	18.5	4	14.8	6	22.2	1	3.7	1	3.7	-	-	6	22.2	4	14.8	1	
	4-9	2	40	-	-	-	-	-	-	-	-	-	-	2	40	1	20	-	

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : FRANCE**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 5	0	3	13.6	-	-	17	77.3	-	-	1	4.5	-	-	-	-	1	4.5	-
	1	12	11.3	-	-	85	80.2	1	0.9	3	2.8	1	0.9	1	0.9	3	2.8	-
	2	18	22.8	9	11.4	32	40.5	7	8.9	2	2.5	-	-	7	8.9	4	5.1	-
	3	7	19.4	1	2.8	5	13.9	3	8.3	1	2.8	1	2.8	9	25	9	25	-
	4-9	1	10	1	10	2	20	-	-	-	-	-	-	3	30	3	30	-
Total Prospective patients Cohorts 1 to 5	0	26	26	-	-	47	47	-	-	12	12	-	-	-	-	15	15	4
Total Prospective patients Cohorts 1 to 4	1	182	38.4	7	1.5	179	37.8	6	1.3	45	9.5	3	0.6	20	4.2	32	6.8	6
	2	123	28.8	70	16.4	84	19.7	23	5.4	18	4.2	8	1.9	83	19.4	18	4.2	1
	3	39	22.8	27	15.8	19	11.1	11	6.4	10	5.8	5	2.9	38	22.2	22	12.9	2
	4-9	7	17.1	8	19.5	4	9.8	5	12.2	-	-	-	-	11	26.8	6	14.6	-
	0	23	29.5	-	-	30	38.5	-	-	11	14.1	-	-	-	-	14	17.9	4
Total Prospective patients Cohorts 1 to 4	1	170	46.2	7	1.9	94	25.5	5	1.4	42	11.4	2	0.5	19	5.2	29	7.9	6
	2	105	30.2	61	17.5	52	14.9	16	4.6	16	4.6	8	2.3	76	21.8	14	4	1
	3	32	23.7	26	19.3	14	10.4	8	5.9	9	6.7	4	3	29	21.5	13	9.6	2
	4-9	6	19.4	7	22.6	2	6.5	5	16.1	-	-	-	-	8	25.8	3	9.7	-
	0	23	29.5	-	-	30	38.5	-	-	11	14.1	-	-	-	-	14	17.9	4

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : FRANCE**

Variable	Statistics	Cohort 1 Prospective patients (N=196) (n %)	Cohort 2 (N=216) (n %)	Cohort 3 (N=116) (n %)	Cohort 4 (N=106) (n %)	Total Prospective patients Cohorts 1 to 4 (N=634)
TTR value, n(%)	n (missing)	65 (131)	112 (104)	62 (54)	44 (62)	283 (351)
	<65	29 (44.6)	50 (44.6)	37 (59.7)	22 (50.0)	138 (48.8)
	>=65	36 (55.4)	62 (55.4)	25 (40.3)	22 (50.0)	145 (51.2)
TTR	n (missing)	65 (131)	112 (104)	62 (54)	44 (62)	283 (351)
	Mean (SD)	67.0 (23.9)	62.3 (26.5)	52.6 (28.3)	58.4 (25.9)	60.6 (26.6)
	Median (IQR)	70.0 (52.6 to 85.3)	68.3 (46.1 to 80.7)	58.1 (33.9 to 72.5)	64.7 (38.2 to 75.7)	65.6 (44.0 to 80.3)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	7.1 to 100.0	0.0 to 100.0
INR value, n(%)	n	728	1322	707	610	3367
	2-3	433 (59.5)	757 (57.3)	353 (49.9)	320 (52.5)	1863 (55.3)
	<2	146 (20.1)	297 (22.5)	198 (28.0)	153 (25.1)	794 (23.6)
	>3	149 (20.5)	268 (20.3)	156 (22.1)	137 (22.5)	710 (21.1)
INR	n	728	1322	707	610	3367
	Mean (SD)	2.6 (0.8)	2.5 (0.9)	2.5 (1.0)	2.6 (0.8)	2.5 (0.9)
	Median (IQR)	2.4 (2.1 to 2.9)	2.4 (2.0 to 2.9)	2.3 (1.9 to 2.9)	2.4 (2.0 to 3.0)	2.4 (2.0 to 2.9)
	Min to Max	1.0 to 8.8	1.0 to 14.5	1.0 to 12.2	1.0 to 8.1	1.0 to 14.5

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : FRANCE**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		1399	87	6.75	(5.47 to 8.32)
	Cardiovascular death	1399	25	1.94	(1.31 to 2.87)
	Non-Cardiovascular death	1399	37	2.87	(2.08 to 3.96)
	Undetermined cause	1399	25	1.94	(1.31 to 2.87)
Stroke/SE		1399	30	2.35	(1.64 to 3.35)
Major bleed		1399	9	0.70	(0.36 to 1.35)
Acute coronary syndrome		1399	7	0.54	(0.26 to 1.14)
Congestive Heart Failure		1399	13	1.01	(0.59 to 1.74)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : FRANCE**

		FRANCE		
Outcome	Cause	N	Events	%
Cardiovascular causes	Ischaemic stroke	25	4	16.00
	Congestive heart failure	25	9	36.00
	Sudden or unwitnessed death	25	4	16.00
	Other	25	8	32.00
Non-cardiovascular causes	Respiratory failure	37	10	27.03
	Infection/sepsis	37	4	10.81
	Malignancy	37	9	24.32
	Other	37	14	37.84

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :FRANCE**

OUTCOME	FRANCE		
	N	Events	%
Stroke(not including systemic embolism)	1399	25	1.79
Primary Ischemic Stroke	1399	20	1.43
<i>of which secondary hemorrhagic ischemic</i>	1399	1	0.07
Undetermined	1399	5	0.36

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : FRANCE**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	35	33.27	1	3.01	(0.42 to 21.34)
1	117	109.48	3	2.74	(0.88 to 8.50)
2	181	166.35	10	6.01	(3.23 to 11.17)
3	309	281.78	18	6.39	(4.03 to 10.14)
4+	720	663.43	53	7.99	(6.10 to 10.46)
Unknown	37	35.54	2	5.63	(1.41 to 22.50)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : FRANCE**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	35	33.27	0	-	-
1	117	108.94	1	0.92	(0.13 to 6.52)
2	181	165.89	2	1.21	(0.30 to 4.82)
3	309	279.59	5	1.79	(0.74 to 4.30)
4+	720	656.35	22	3.35	(2.21 to 5.09)
Unknown	37	35.54	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : FRANCE**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	35	33.27	0	-	-
1	117	109.25	1	0.92	(0.13 to 6.50)
2	181	165.41	1	0.61	(0.09 to 4.29)
3	309	281.78	0	-	-
4+	720	659.63	7	1.06	(0.51 to 2.23)
Unknown	37	35.54	0	-	-